Elicio Therapeutics, Inc. Common Stock

Elicio Therapeutics, a clinical-stage biotechnology company, will host a virtual event on June 25, 2025, to discuss its lead product candidate, ELI-002, an AMP-powered therapeutic vaccine for the treatment of KRAS mutation-driven pancreatic cancer. The event will feature insights from leading experts in the field.

Related tickers: ELTX.

BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying common warrants. All of the common stock, pre-funded warrants and accompanying common warrants are being offered by Elicio. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Related tickers: ELTX.